Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA

Journal of Neural Transmission

Volumn 115, Issue 7, 2008, Pages 1001-1009

  Bartels, A L ^a   Willemsen, A T M ^b   Kortekaas, R ^b   De Jong, B M ^a   De Vries, R ^a   De Klerk, O ^b   Van Oostrom, J C H ^a   Portman, A ^a   Leenders, K L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Alzheimer; Blood brain barrier; MSA; Neurodegeneration; P glycoprotein; Parkinson; PET; PSP; Verapamil

Indexed keywords

AMANTADINE; CARBON 11; DOPAMINE RECEPTOR STIMULATING AGENT; GLYCOPROTEIN P; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; VERAPAMIL;

ADULT; AGED; ARTICLE; BASAL GANGLION; BLOOD BRAIN BARRIER; BRAIN ATROPHY; BRAIN MAPPING; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE COURSE; FRONTAL LOBE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MESENCEPHALON; MULTISYSTEM ATROPHY; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROTOXICITY; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN TRANSPORT; STATISTICAL PARAMETERS; STATISTICAL PARAMETRIC MAPPING; TISSUE DISTRIBUTION; WHITE MATTER;

AGED; BLOOD-BRAIN BARRIER; BRAIN MAPPING; CARBON ISOTOPES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; P-GLYCOPROTEIN; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; SUPRANUCLEAR PALSY, PROGRESSIVE; VERAPAMIL;

EID: 46649085260     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-008-0030-y     Document Type: Article

References (47)

1. Bain LJ, LeBlanc GA (1996) Interaction of structurally diverse pesticides with the human MDR1 gene product P-glycoprotein. Toxicol Appl Pharmacol 141:288-298
2. Bartels AL, van Berckel BNM, Lubberink M, Luurtsema G, Lammertsma AA, Leenders KL (2007) Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease. Final stage of review ed
3. Begley GS, Horvath AR, Taylor JC, Higgins CF (2005) Cytoplasmic domains of the transporter associated with antigen processing and P-glycoprotein interact with subunits of the proteasome. Mol Immunol 42:137-141
4. Braak H, Braak E (2000) Pathoanatomy of Parkinson's disease. J Neurol 247:3-10
5. Burn DJ (2006) Parkinson's disease dementia: what's in a Lewy body? J Neural Transm Suppl 361-365
6. Caparros-Lefebvre D, Lees AJ (2005) Atypical unclassifiable parkinsonism on Guadeloupe: an environmental toxic hypothesis. Mov Disord 20(Suppl 12):S114-S118
7. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sides. Proc Natl Acad Sci USA 86:695-698
8. Davis PH, Golbe LI, Duvoisin RC, Schoenberg BS (1988) Risk factors for progressive supranuclear palsy. Neurology 38:1546-1552
9. de Lange ECM (2004) Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. Adv Drug Deliv Rev 56:1793-1809
10. Del TK, Rub U, de Vos RA, Bohl JR Braak H (2002) Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 61:413-426
11. Demeule M, Labelle M, Regina A, Berthelet F, Beliveau R (2001) Isolation of endothelial cells from brain, lung, and kidney: Expression of the multidrug resistance P-glycoprotein isoforms. Biochem Biophys Res Commun 281:827-834
12. Drozdzik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J, Sych Z (2003) Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 13:259-263
13. Fernandez C, Buyse M, German-Fattal M, Gimenez F (2004) Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality. J Pharm Pharm Sci 7:359-371
14. Friston KJ, Frith CD, Liddle PF, Frackowiak RSJ (1991) Comparing functional (pet) images-the assessment of significant change. J Cereb Blood Flow Metab 11:690-699
15. Fromm MF (2000) P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 38:69-74
16. Furuno T, Landi MT, Ceroni M, Caporaso N, Bernucci I, Nappi G, Martignoni E, Schaeffeler E, Eichelbaum M, Schwab M, Zanger UM (2002) Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 12:529-534
17. Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56:33-39
18. Gerhard A, Banati RB, Cagnin A, Brooks DJ (2001) In vivo imaging of activated microglia with [C-11]PK11195 positron emission tomography (PET) in idiopathic and atypical Parkinson's disease. Neurology 56:A270
19. Gilman S, Low P, Quinn N, Albanese A, Ben-Shlomo Y, Fowler C, Kaufmann H, Klockgether T, Lang A, Lantos P, Litvan I, Mathias C, Oliver E, Robertson D, Schatz I, Wenning G (1999) Consensus on the diagnosis of multi-system atrophy. Neurologia 14:425-428
20. Green J, McDonald WM, Vitek JL, Evatt M, Freeman A, Haber M, Bakay RA, Triche S, Sirockman B, DeLong MR (2002) Cognitive impairments in advanced PD without dementia. Neurology 59:1320-1324
21. Hendrikse NH, Vaalburg W, De Vries EG, Van der Graaf WT, Willemsen AT (1999) Quantification of in-vivo P-glycoprotein facilitated transport in the blood-brain barrier. J Nucl Med 40:261P-262P
22. Hendrikse NH, Bart J, De Vries EGE, Groen HJM, Van der Graaf WTA, Vaalburg W (2001) P-glycoprotein at the blood-brain barrier and analysis of drug transport with positron-emission tomography. J Clin Pharmacol 48S-54S
23. Hennessy M, Kelleher D, Spiers JP, Barry M, Kavanagh P, Back D, Mulcahy F, Feely J (2002) St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 53:75-82
24. Johnson WG (2000) Late-onset neurodegenerative diseases-the role of protein insolubility. J Anat 196(Pt 4):609-616
25. Kortekaas R, Leenders KL, van Oostrom JCH, Vaalburg W, Bart J, Willemsen ATM, Hendrikse NH (2005) Blood-brain barrier dysfunction in Parkinsonian midbrain in vivo. Ann Neurol 57:176-179
26. Kuhnke D, Jedlitschky G, Grube M, Krohn M, Jucker M, Mosyagin I, Cascorbi I, Walker LC, Kroemer HK, Warzok RW, Vogelgesang S (2007) MDR1-P-Glycoprotein (ABCB1) mediates transport of Alzheimer's amyloid-beta peptides-implications for the mechanisms of Abeta clearance at the blood-brain Barrier. Brain Pathol (4):347-353
27. Lam FC, Liu R, Lu P, Shapiro AB, Renoir JM, Sharom FJ, Reiner PB (2001) beta-Amyloid efflux mediated by p-glycoprotein. J Neurochem 76:1121-1128
28. Langford D, Grigorian A, Hurford R, Adame A, Ellis RJ, Hansen L, Masliah E (2004) Altered P-glycoprotein expression in AIDS patients with HIV encephalitis. J Neuropathol Exp Neurol 63:1038-1047
29. Lee JM, Markus HS (2006) Does the white matter matter in Alzheimer disease and cerebral amyloid angiopathy? Neurology 66:6-7
30. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS, Chase TN, FitzGibbon EJ, Hall Z, Juncos J, Nelson KB, Oliver E, Pramstaller P, Reich SG, Verny M (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP International Workshop. Neurology 47:1-9
31. Logan J (2000) Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol 27:661-670
32. Mcgeer PL, Mcgeer EG (1998) Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alzheimer Dis Assoc Disord 12:S1-S6
33. Mcgeer PL, Mcgeer EG (2004) Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 10:S3-S7
34. Mcrae MP, Brouwer KLR, Kashuba ADM (2003) Cytokine regulation of P-glycoprotein. Drug Metab Rev 35:19-33
35. Morfini G, Pigino G, Opalach K, Serulle Y, Moreira JE, Sugimori M, Llinas RR, Brady ST (2007) 1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C. Proc Natl Acad Sci USA 104:2442-2447
36. Norris EH, Uryu K, Leight S, Giasson BI, Trojanowski JQ, Lee VM (2007) Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. Am J Pathol 170:658-666
37. Piccini P, Pavese N, Canapicchi R, Paoli C, Del DP, Puglioli M, Rossi G, Bonuccelli U (1995) White matter hyperintensities in Parkinson's disease. Clin Correlat Arch Neurol 52:191-194
38. Rajput AH (2001) Environmental toxins accelerate Parkinson's disease onset. Neurology 56:4-5
39. Roher AE, Kuo YM, Esh C, Knebel C, Weiss N, Kalback W, Luehrs DC, Childress JL, Beach TG, Weller RO, Kokjohn TA (2003) Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer's disease. Mol Med 9:112-122
40. Saito Y, Kawashima A, Ruberu NN, Fujiwara H, Koyama S, Sawabe M, Arai T, Nagura H, Yamanouchi H, Hasegawa M, Iwatsubo T, Murayama S (2003) Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol 62:644-654
41. Tan EK, Drozdzik M, Bialecka M, Honczarenko K, Klodowska-Duda G, Teo Y, Tang K, Wong LP, Chong SS, Tan C, Yew K, Zhao Y, Lee CGL (2004) Analysis of MDR1 haplotypes in Parkinson's disease in a white population. Neurosci Lett 372:240-244
42. Tan B, Piwnica-Worms D, Ratner L (2000) Multidrug resistance transporters and modulation. Curr Opin Oncol 12:450-458
43. Tan KH, Purcell WM, Heales SJR, Mcleod JD, Hurst RD (2002) Activated T cells modulate P-glycoprotein expression in an in vitro model of the blood-brain barrier. J Physiol (London) 539:89P
44. Vogelgesang S, Cascorbi I, Kroemer HK, Schroeder E, Pahnke J, Siegmund W, Keil C, Warzok RW, Walker LC (2001) Deposition of amyloid is inversely correlated with the expression of p-glycoprotein-implications on the possibility of prevention of Alzheimer's disease. Acta Neuropathol 102:545
45. Vogelgesang S, Glatzel M, Walker LC, Kroemer HK, Aguzzi A, Warzok RW (2006a) Cerebrovascular P-glycoprotein expression is decreased in Creutzfeldt-Jakob disease. Acta Neuropathol (Berl) 111:436-443
46. Vogelgesang S, Kuhnke D, Jedlitschky G, Jucker M, Mosyagin I, Pahnke J, Cascorbi I, Kroemer HK, Walker LC, Warzok RW (2006b) P-glycoprotein (ABCB1) mediates transport of Alzheimer's beta-amyloid peptides. Acta Neuropathol 112:365-367
47. Wegman TD, Maas B, Elsinga PH, Vaalburg W (2002) An improved method for the preparation of [C-11]verapamil. Appl Radiat Isot 57:505-507